What the FDA labels say about taking them together
Aliskiren and enalapril
Enalapril's FDA label of January 23, 2026 names aliskiren in its contraindications section; aliskiren's label does not name enalapril itself but warns about its class (ACE inhibitors). The enalapril label: “Do not coadminister aliskiren with VASOTEC in patients with diabetes.”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the enalapril FDA label on DailyMed (effective January 23, 2026, Bausch Health US LLC).
What does the aliskiren label say about enalapril?
Aliskiren's label does not name enalapril itself; it warns about its class (ACE inhibitors):
Aliskiren label, warnings and precautionsIn general, avoid combined use of Tekturna with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) less than 60 mL/min [see Contraindications ( 4 ), Drug Interactions ( 7 ) and Clinical Studies ( 14.3 )].
Aliskiren label, drug interactionsIn general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min.
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the enalapril label say about aliskiren?
Enalapril label, contraindicationsDo not coadminister aliskiren with VASOTEC in patients with diabetes (see PRECAUTIONS , Drug Interactions ).
Enalapril label, drug interactionsDual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Epaned, NDA208686), Azurity Pharmaceuticals, Inc., effective December 16, 2025 (SPL set e6dbda02-779e-420c-893d-d0fea09432be), via openFDA
Source: FDA drug label (Vasotec), Bausch Health US LLC, effective January 23, 2026 (SPL set 39631f1f-5d19-43c1-b504-bf56d991ed97), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Enalapril | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Heart failure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.0664 per tablet 10 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once